Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical Outcomes Associated with Single STK11 Mutations and Those Co-occurring with KEAP1 and KRAS Mutations in Metastatic Non-Small Cell Lung Cancer.

Advances in therapy·2026

Same author

Prophylactic Versus Therapeutic Sucralfate in Patients at High Risk for Radiation Esophagitis: Randomized Controlled Trial.

Practical radiation oncology·2026

Same author

Futile Radiotherapy for Patients With Cancer Near the End of Life.

JAMA network open·2026

Same author

Short-term oxycodone exposure produces delayed and persistent gut microbiome disruption in mice.

bioRxiv : the preprint server for biology·2026

Same author

The evolution of non-surgical management in stage III non-small cell lung cancer.

BJC reports·2026

Same author

Impact of acromegaly subtypes on survival: results from a large multicenter cohort.

Journal of the Endocrine Society·2026

Search research articles

Related Experiment Video

Updated: Nov 3, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Local Ablative Therapy in Oligometastatic NSCLC.

Xingzhe Li¹, Daniel Gomez¹, Puneeth Iyengar²

¹Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

Seminars in Radiation Oncology

|June 6, 2021

Summary

Aggressive local ablative therapy (LAT) shows promise for oligometastatic non-small cell lung cancer (NSCLC). Further research is needed to refine patient selection and confirm benefits in survival for this unique cancer subtype.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Related Experiment Videos

Last Updated: Nov 3, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Area of Science:

Oncology
Pulmonology
Radiation Oncology

Background:

Oligometastatic non-small cell lung cancer (NSCLC) is a distinct clinical entity.
Retrospective studies and early trials suggest aggressive treatment efficacy.
Recent randomized trials indicate survival benefits from local ablative therapy (LAT).

Purpose of the Study:

To review clinical and biologic data for patient selection in oligometastatic NSCLC.
To discuss the role of LAT in managing oligometastatic NSCLC.
To outline future directions for prospective and translational studies.

Main Methods:

Review of retrospective series and early phase single arm trials.
Analysis of recent randomized trials evaluating LAT.
Discussion of clinical and biologic data for patient selection.

Main Results:

LAT, including radiation therapy and surgery, shows potential for prolonging disease-free and overall survival.
Evidence suggests efficacy and safety of aggressive approaches in select patients.
Existing clinical evidence has limitations, and validated biomarkers are lacking.

Conclusions:

LAT is a promising approach for select patients with oligometastatic NSCLC.
Further research, including late-stage randomized trials with correlatives, is crucial.
Improved patient selection and biomarker validation are key for optimizing LAT in NSCLC treatment.